Birmingham’s AI Metrics is partnering with a UK-based company to distribute its virtual liver biopsy software in a deal that could help stem the spread of chronic liver disease.

IQ-AI Limited will globally distribute AI Metrics’ virtual liver biopsy software. The agreement, with IQ-AI subsidiary Imaging Biometrics, will enable chronic liver disease assessment using commonly acquired computed tomography, or CT, images.

More than 20 million deaths worldwide are attributed to chronic liver disease. AI Metrics developed LSN technology to non-invasively assess the nodules, or bumps, on the liver’s surface. This information, when used by trained clinicians, may aid in the diagnosis and staging of chronic liver disease.

Currently, clinicians assess patient liver condition through surgical biopsy, which is prone to sampling error, pain, bleeding and other complications. Specialized MRI or ultrasound equipment can be used in certain cases, but patient fasting is required.

LSN analysis uses common CT scanning technology and proprietary software for accurate, low-risk assessment of CLD, and prior CT scans can be used to retroactively assess disease progression, the company says.

AI Metrics worked with Imaging Biometrics to complete the translation of the LSN technology to routine clinical and research use. Along with software development services, IB offered its regulatory expertise, and is assisting AI Metrics in seeking clearance for marketing in Europe and the U.S.

“We are excited about partnering with Imaging Biometrics as we introduce LSN technology to the worldwide market,” AI Metrics CEO Andrew Smith said. “Their development efforts have been integral to bringing LSN from promising research to commercial introduction, and the continuity of our relationship moving forward will ensure that LSN can quickly gain widespread utilization.”